Prosecution Insights
Last updated: April 19, 2026
Application No. 17/620,946

ANHYDROUS COMPOSITION COMPRISING AT LEAST ONE AMINO SILICONE, AT LEAST ONE ALKOXYSILANE AND AT LEAST ONE COLORING AGENT

Non-Final OA §103
Filed
Dec 20, 2021
Examiner
RONEY, CELESTE A
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
L'Oréal
OA Round
2 (Non-Final)
62%
Grant Probability
Moderate
2-3
OA Rounds
2y 12m
To Grant
81%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allow Rate
452 granted / 723 resolved
+2.5% vs TC avg
Strong +19% interview lift
Without
With
+18.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 12m
Avg Prosecution
68 currently pending
Career history
791
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
54.0%
+14.0% vs TC avg
§102
5.9%
-34.1% vs TC avg
§112
19.8%
-20.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 723 resolved cases

Office Action

§103
DETAILED ACTION Previous Rejections Applicant’s arguments, filed 07/07/2025, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Response to Arguments Applicant’s arguments with respect to claim(s) 18 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Claim Rejections - 35 USC § 103 - Obviousness The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 18, 22-23, 24-25, 26-28 and 31-34 are rejected under 35 U.S.C. 103 as being unpatentable over Nguyen et al (US 2013/0129648 A1), in view of Khenniche et al (WO 2012/055805 A1). Nguyen taught an anhydrous composition [0299] comprising: at least one amino silicone [0026, 0072]; aminopropyl triethoxysilane (e.g., reads on the instant Formula VIII of claim 18b; reads on the instant Formula VIIIa of claims 24-25) [0026]; and direct dyes (e.g., at least one coloring agent) [0032]. Nguyen was directed to hair compositions [abstract]. Although Nguyen generally taught amino silicones, as previously discussed, Nguyen was not specific the claimed silicones of the instantly recited claims 18 and 20-21. Khenniche taught hair compositions [claim 16, abstract] in anhydrous form [page 51, lines 15-22] comprising amino silicones, wherein the amino silicones corresponded to the general formula (III) [page 12]: PNG media_image1.png 250 515 media_image1.png Greyscale As per Khenniche [page 12, lines 3-7], R, R′ and R″, were identical or different, denote a C1-C4 alkyl radical, preferably CH3; a C1-C4 alkoxy radical, preferably methoxy; or an OH radical; A represents a linear or branched, C3-C8 and preferably C3-C6 alkylene radical; m and n are integers dependent on the molecular weight and whose sum is between 1 and 2000. In another embodiment, R, R' and R", which were identical or different, represented a C1-C4 alkyl or hydroxyl group, A represented a C3 alkylene group and m and n were such that the weight-average molecular mass of the compound was between 5000 and 500000 approximately [page 12, lines 8-12]. The Examiner notes that Khenniche’s formulas read on the instant claims 18 and 20-21. Since Nguyen generally taught amino silicones, it would have been prima facie obvious to one of ordinary skill in the art to include, within Nguyen, the amino silicones of Khenniche. Generally, it is prima facie obvious to select a known material for incorporation into a composition, based on its recognized suitability for its intended use. See MPEP 2144.07. In the instant case, it is prima facie obvious to select an amino silicone for incorporation into a hair composition, based on its recognized suitability for its intended use as such, as taught by Khenniche. Nguyen, in view of Khenniche, reads claims 18, 20-21, 24-27 and 33. Claims 22-23 are rendered prima facie obvious because Nguyen taught silicone amines present at from about 1 % to about 50 %; or from about 1 % to about 25 %, based on the weight of the compositions [0078]. The instant claim 22 recites from about 0.1 % to 40 % amino silicone. The instant claim 23 recites from about 1 % to 25 % amino silicone. Nguyen taught silicone amines present at from about 1 % to about 50 %; or from about 1 % to about 25 %. In the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art", a prima facie case of obviousness exists. MPEP 2144.05 A. Claim 28 is rendered prima facie obvious because Nguyen taught aminopropyl triethyoxysilane as a silicone amine [0026], where silicone amines were taught in amounts from about 1 % to about 25 %, or from about 1 % to about 50 % [0028]. The instant claim 28 recites the alkoxysilane present from 0.1 % to 30 %. Nguyen taught aminopropyl triethyoxysilane present at about 1 % to about 25 %, or from about 1 % to about 50 %. A prima facie case of obviousness exists because of overlap, as discussed above. Claim 31 is rendered prima facie obvious because Nguyen taught pigments present at from about 0.5 % to about 40 % [0032]. The instant claim 31 recites from 0.05 % to 30 % pigment. Nguyen taught pigments present at from about 0.5 % to about 40 %. A prima facie case of obviousness exists because of overlap, as discussed above. Claim 32 is rendered prima facie obvious because Nguyen taught that the composition may contain less than 3 % of water [0300]. Claim 34 is rendered prima facie obvious because Nguyen taught aminopropyl triethyoxysilane as a silicone amine [0026], where silicone amines were taught in amounts from about 1 % to about 90 % [0028]. In another embodiment, silicone amines were taught as being present in amounts from about 1 % to about 90 % [0078]. The instant claim 34 recites the mass ratio of the alkokysilane of Formula (VIII) to the amino silicone from 95:5 to 5:95. Nguyen taught aminopropyl triethoxysilane at 1 % to 90 % and silicone amines at 1 % to 90 %. A prima facie case of obviousness exists because of overlap, as discussed above. Claim(s) 29-30 are rejected under 35 U.S.C. 103 as being unpatentable over Nguyen et al (US 2013/0129648 A1), in view of Khenniche et al (WO 2012/055805 A1) and further in view of Plos et al (ES 2981323 T3). The 35 U.S.C. 103 rejection over Nguyen and Khenniche was previously described. Additionally, Nguyen generally taught organic solvents as hydrocarbons [0228]. Although Nguyen generally taught organic solvents as hydrocarbons, Nguyen was not specific oils chosen from C8-C16 alkanes, as recited in claims 29-30. Nevertheless, Plos taught anhydrous compositions [page 7, 12th paragraph] for the hair comprising silicones and alkoxysilanes [title], and further comprising isododecane as an organic solvent [page 8, 4th paragraph]. Since Nguyen generally taught hydrocarbon organic solvents, it would have been prima facie obvious to one of ordinary skill in the art to include, within Nguyen, Plos’ isododecane. Generally, it is prima facie obvious to select a known material for incorporation into a composition, based on its recognized suitability for its intended use. See MPEP 2144.07. In the instant case, it is prima facie obvious to select isododecane for incorporation into a hair composition, based on its recognized suitability for its intended use as an organic solvent, as taught by Plos at page 8, 4th paragraph. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CELESTE A RONEY whose telephone number is (571)272-5192. The examiner can normally be reached Monday-Friday; 8 AM-6 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Frederick Krass can be reached at 571-272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CELESTE A RONEY/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Dec 20, 2021
Application Filed
Mar 02, 2025
Non-Final Rejection — §103
Jul 07, 2025
Response Filed
Oct 11, 2025
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599573
COMPOSITIONS AND USES THEREOF IN TREATING CANCERS
2y 5m to grant Granted Apr 14, 2026
Patent 12599559
CD1D-LIGAND-COMPOUND-CONTAINING LIPOSOME PREPARATION HAVING IMPROVED PHARMACOKINETICS
2y 5m to grant Granted Apr 14, 2026
Patent 12594232
PERSONAL CARE COMPOSITIONS AND METHODS FOR USING SUCH COMPOSITIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12589169
COMPOUND AND MRI CONTRAST AGENT CONTAINING SAME
2y 5m to grant Granted Mar 31, 2026
Patent 12582353
EVALUATING DRUG EFFICACY BY USING WEARABLE SENSORS
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
62%
Grant Probability
81%
With Interview (+18.8%)
2y 12m
Median Time to Grant
Moderate
PTA Risk
Based on 723 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month